Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.
Immix Biopharma Inc a biotechnology company pioneering Tissue Specific Therapeutics TSTxTM for oncology and inflammation today announced that the US Food and Drug Administration FDA has granted orphan drug designation ODD to IMX for the treatment of...
Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease announced today the launch of an enhanced version of...
Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co Ltd announced a geographicallyfocused exclusive collaboration and license agreement to commercialize JR INN pabinafusp alfa an investigational nextgeneration recombinant fusion protein...
More than million Americans struggle with drug addiction while only receive treatment Prime Therapeutics LLC Prime and Pear Therapeutics Inc Pear have developed a comprehensive valuebased agreement for prescription digital therapeutics PDTs This va...
Mirum Pharmaceuticals Inc a leader in rare liver disease today announced that the US Food and Drug Administration FDA has approved LIVMARLI maralixibat oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome ALGS on...
Abbott today announced that the US Food and Drug Administration FDA has approved the companys Amplatzer Talisman PFO Occlusion System to treat people with a patent foramen ovale PFO a small opening between the upper chambers of the heart who are at...
Lantern Pharma a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence AI platform to transform the cost pace and timeline of oncology drug discovery and development and Deep Lens a digital healthcare company foc...
AbbVie announced that the US Food and Drug Administration FDA approved QULIPTA atogepant for the preventive treatment of episodic migraine in adults QULIPTA is the first and only oral calcitonin generelated peptide CGRP receptor antagonist gepant spe...
Catalyst Biosciences Inc announced that the US Food and Drug Administration FDA has granted Orphan Drug Disease Designation ODD for its lead product candidate subcutaneous Marzeptacog alfa activated or MarzAA for the treatment of Factor VII Deficienc...
Chemomab Therapeutics Ltd a clinicalstage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need today announced a research collaboration with Leeds University t...
